無料プレビュー

BeOne Medicines AG (ONC) · NASDAQ

プロフィール

BeOne Medicines Ltd. is a global oncology company discovering and developing innovative treatments targeting cancer patients worldwide. The company's marketed products include BRUKINSA (BTK inhibitor for B-cell malignancies), TEVIMBRA (anti-PD-1 antibody for solid tumors), and PARTRUVIX (PARP inhibitor), along with in-licensed products commercialized primarily in China. BeOne operates through wholly-owned manufacturing facilities and a global clinical development infrastructure spanning six continents, positioned across hematologic and solid tumor oncology segments with an internal R&D pipelin

主要指標

株価: $350.13 (-3.82%)
時価総額: 374億ドル
PER（今期予想）: 48.1
PBR: 10.5
配当利回り: —
52週レンジ: $253.95 – $385.22
業種: Healthcare / Biotechnology
上場: NASDAQ
構成銘柄: —

比較会社: VRTX Vertex Pharmaceuticals Incorporated、MRNA Moderna, Inc.、REGN Regeneron Pharmaceuticals, Inc.、ARGX argenx SE、SGEN Seagen Inc.、RVMD Revolution Medicines, Inc.、ALNY Alnylam Pharmaceuticals, Inc.、ROIV Roivant Sciences Ltd.

長期トレンド・直近動向・強気／弱気シナリオ・業績10年・バリュエーション・テクニカル・株主・役員・深掘り分析は会員向けです。

7日間無料で全文を読むログイン

次回決算: 2026-11-05 · 更新: 2026-10-09